Clinical Trial Update: Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating tislelizumab in combination with sitravatinib for locally advanced or metastatic non-small cell lung cancer was terminated, and results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Sitravatinib (sitravatinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: BeiGene | Conditions: Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | Status: TERMINATED | Results posted: 2025-06-29